News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexCryptocurrenciesCybersecurityPress Releases

Biohaven's drug for neurological disease fails late-stage study

05/23/2022 | 07:46am EDT

May 23 (Reuters) - Biohaven Pharmaceutical said on Monday its experimental drug for patients with spinocerebellar ataxia, a genetic disease that affects the nervous system, failed to meet the main goal of a late-stage study.

Spinocerebellar ataxia (SCA) is a progressive disorder caused by the degeneration of cells in the brain and spinal cord and can lead to symptoms such as uncoordinated movement and muscle wasting. It has no approved treatments in the United States.

The main goal in the Biohaven study measured the change in severity of symptoms among patients who took the drug, troriluzole, from the baseline to week 48 of treatment.

Biohaven said patients in both the drug and placebo group showed a less-than-expected change in disease progression, which led to the study not reaching statistical significance.

But troriluzole showed some benefit compared with placebo in patients with SCA Type 3 - the most common form of the disease, Biohaven said.

The company plans to share the data on the subtype with regulators and said it would work with the U.S. Food and Drug Administration (FDA) on a path forward for the drug.

Biohaven earlier this month agreed to be bought by Pfizer Inc in a $11.6 billion deal that underscored the buyer's confidence in its commercial migraine drug.

Separately, the company said on Monday the U.S. FDA has accepted the marketing application for its zavegepant nasal spray to treat migraine in adults, with a decision expected in the first quarter of 2023.

(Reporting by Leroy Leo and Amruta Khandekar in Bengaluru; Editing by Aditya Soni)


© Reuters 2022
Latest news "Economy & Forex"
06:12aZimbabwe healthcare workers temporarily call off wage strike
RE
06:08aU.S.'s Russia sanctions architect Singh departs as Ukraine war drags on
RE
06:03aIn post-Roe U.S., abortion providers seek licenses across state lines
RE
05:51aCongo Republic oil workers plan hunger strike and work stoppages next week
RE
05:47aQatar's Emir arrives in Egypt in first official visit since boycott
RE
05:39aBurkina Faso gives civilians 14 days to evacuate ahead of military operations
RE
05:34aAs deadline looms, countries struggle to agree on protecting nature
RE
05:25aFrance's Amethis sells Kenyan retailer stake to Mauritius-based IBL
RE
05:24aMali junta passes new electoral law
RE
05:20aHostel in Rwanda for UK asylum seekers prepares to take children
RE
Latest news "Economy & Forex"